Socio-economic burden of rare diseases: A systematic review of cost of illness evidenceAris Angelis, Panos Kanavos(London School of Economics and Political Science)Health PolicyDecember 30, 201410.1016/j.healthpol.2014.12.016Cited by 303SaveCiteExport RISWatch citationsRelated PapersImpact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries|BMC Health Services Research|2022|21